These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14692526)

  • 1. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
    Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
    Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
    Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
    Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma.
    Ozgüroglu M; Turna H; Demir G; Döventas A; Demirelli F; Mandel NM; Büyükünal E; Serdengeçti S; Berkarda B
    Am J Clin Oncol; 1999 Dec; 22(6):615-8. PubMed ID: 10597748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
    Batlle M; Ribera JM; Oriol A; Pastor C; Mate JL; Fernández-Avilés F; Flores A; Millá F; Feliu E
    Leuk Lymphoma; 2005 Oct; 46(10):1471-6. PubMed ID: 16194893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
    Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
    Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
    Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P
    Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
    Zidan J; Hussein O; Basher W; Zohar S
    Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved prognostic parameter for non-Hodgkin's lymphoma based on the combination of three serum tumor markers.
    Gui W; Wang T; Wang J; Wang L; He J; Yang B; Zhao Z; Zhang H; Zhang Q
    Int J Biol Markers; 2008; 23(4):207-13. PubMed ID: 19199267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA 125 levels in children with non-Hodgkin's lymphoma.
    Kutluk T; Varan A; Erbaş B; Büyükpamukçu M
    Pediatr Hematol Oncol; 1999; 16(4):311-9. PubMed ID: 10407867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
    Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
    Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma.
    Zacharos ID; Efstathiou SP; Petreli E; Georgiou G; Tsioulos DI; Mastorantonakis SE; Christakopoulou I; Roussou PP
    Eur J Haematol; 2002 Oct; 69(4):221-6. PubMed ID: 12431241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
    Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
    Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies.
    Dilek I; Ayakta H; Demir C; Meral C; Ozturk M
    Clin Lab Haematol; 2005 Feb; 27(1):51-5. PubMed ID: 15686508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy.
    Morra E
    Int J Biol Markers; 1999; 14(3):149-53. PubMed ID: 10569136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of serum lactate dehydrogenase, β2-microglobulin and vascular endothelial growth factor level detection in patients with non-Hodgkin's lymphoma].
    Duan Y; Li G; Hu HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):608-10. PubMed ID: 22739165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma.
    Avilés A; Díaz-Maqueo JC; Rodriguez L; García EL; Guzmán R; Talavera A
    Hematol Oncol; 1991; 9(2):115-21. PubMed ID: 1869242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Ca 125 levels in children with acute leukemia and lymphoma.
    Birgen D; Ertem U; Duru F; Sahin G; Yüksek N; Bozkurt C; Karacan CD; Aksoy C
    Leuk Lymphoma; 2005 Aug; 46(8):1177-81. PubMed ID: 16085559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum CA 125 levels in patients with chronic lymphocytic leukemia.
    Bairey O; Shaklai M
    Clin Lab Haematol; 2005 Feb; 27(1):57-60. PubMed ID: 15686509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.